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NicheMusculoskeletal disorders including osteoarthritis (OA) represent a
major cause of disability and morbidity, and cause an enormous burden
for health and social care systems globally. In the Global Burden of
Disease 2010 study, hip and knee OAwas ranked as the 11th highest con-
tributor to global disability (Cross et al., 2014), and its prevalence is set to
increase in parallel with the number of people aged 60 years and older.
Articular cartilage within synovial joints has limited self-repair capacity
because of its avascular nature and the low proliferation rate of
chondrocytes, the main cell type responsible for its maintenance.
Chondrocytes reside in a unique niche of cartilage extracellular matrix
(ECM) that consists of collagen type II, large aggregating proteoglycans
(e.g. aggrecan), glycosaminoglycans, hyaluronan, other non-collagenous
proteins (e.g. COMP), and a large amount of water and mobile cations
(i.e. Na+, K+, Ca2+); this composition allows cartilage to resist biome-
chanical forces (Jahr et al., 2015). Cell-based therapies are rapidly being
developed in a number of diseases including bone and joint disorders.⁎ Corresponding author at: Faculty of Health andMedical Sciences, University of Surrey,
Guildford, Surrey GU2 7XH, United Kingdom.
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2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article underAs OA is currently incurable, novel biological and cell-based therapies
that can effectively treat joint degeneration are high priorities in regener-
ative medicine.
Multipotentmesenchymal stem cells (MSCs) derived from bonemar-
row, adipose tissue and umbilical cord (UC) show considerable promise
for use in cartilage repair. Under appropriatemicro-environmental condi-
tions they can proliferate and give rise to chondrocytes and other related
mesenchymal cell phenotypes, allowing them to act as key players in
regenerating injured tissue following injury and trauma (Richardson
et al., 2015). Another key feature ofMSCs is their capacity tomodulate im-
mune responses in vitro and in vivo, making them well-suited for the
treatment of systemic inﬂammatory and autoimmune conditions that af-
fect synovial joints. Their immunosuppressive nature extends to both the
innate and adaptive immune system through interactions with dendritic
cells, natural killer cells, macrophages and B and T lymphocytes bymeans
of cell–cell contacts or soluble mediators (Burr et al., 2013). Given the
avascular and alymphatic characteristics of articular cartilage and the spe-
ciﬁc features of the ECM that can shield theMHCmolecules from recogni-
tion byhost cells, an immune response against allogeneic chondrocytes or
osteochondral constructs in the host has not been reported. However, the
immunomodulatory effects of MSCs may have critical outcomes in
diseases of the musculoskeletal system where an inﬂammatory or auto-
immune process is at the core of themain disease. Themolecular mecha-
nisms underlying the effects of MSCs on the immune system are diverse
and employ the release of soluble factors such as interleukin-10, tumour
necrosis factor-alpha, transforming growth factor-beta, prostaglandin-E2
and indoleamine-2,3-dioxygenase by MSCs. UC-MSCs express the HLA-E,
HLA-F and HLA-G non-canonical type I MHC receptors. In addition,
the fact that B7-H3 (CD276), a co-stimulatory molecule that inhibits T
cell activation, was demonstrated to be expressed not only in undifferen-
tiated UC-MSCs but persisted following differentiation towards the
chondrogenic lineage indicate that differentiated UC-MSCs continue to
have immunosuppressive characteristics, which is an added advantage
with potentially important clinical implications (La Rocca et al., 2013).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. In addition to their regenerative properties, the immunoregulatory potential of MSCs
make them ideal for use as therapeutic agents as they are uniquely positioned to suppress
local inﬂammation and at the same time participate in tissue repair. MSCs isolated from
the bone marrow (as shown here) or elsewhere employ diverse molecular mechanisms to
modulate the immune system including expression of cell surface receptors (HLA-E, HLA-F
and HLA-G non-canonical type I MHC receptors, as well as the co-stimulatory molecule B7-
H3 (CD276) that inhibits T cell activation) and the secretion of soluble mediators (IL-10, in-
terleukin-10; TNF-α, tumour necrosis factor-alpha; TFG-β, transforming growth factor-beta;
PGE2, prostaglandin-E2; IDO, indoleamine-2,3-dioxygenase). Please note that this list is not
exhaustive.
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them ideal for use as therapeutic agents in vivo as they are uniquely po-
sitioned to suppress local inﬂammation and at the same time initiate
tissue repair (Fig. 1). However, directing stem cell fate decisions to-
wards a speciﬁc lineage is inﬂuenced by a variety of external and inter-
nal factors (Kobolak et al., 2015), which are still not completely
elucidated. To successfullymicroengineer the nativemicroenvironment
of the cartilage ECM and the chondrocyte niche, it is critical to fully un-
derstand, and if needed, precisely modulate the molecular steps in-
volved in chondrogenesis. This approach could be facilitated by using
biomaterials thatmimic the native ECM in combinationwith the neces-
sary biophysical cues required for cellular remodelling (Jahr et al.,
2015). Depending on the speciﬁc properties of the biomaterial under in-
vestigation, a variety of biophysical parameters such as swelling or po-
rosity can be engineered to induce changes in cell spreading, migration
and differentiation.
New biomimetic biomaterials are now being developed for micro-
engineering the unique niche in articular cartilage, taking advantage ofthe integration of mechanical and topographical properties of materials
in scaffold design, and incorporation of biochemical cues such as
cytokines in tethered, soluble, or time-released forms (Edalat et al.,
2012; Zorlutuna et al., 2013). For example, ﬁbrous poly(glycerol
sebacate):poly(caprolactone) (PGS:PCL) scaffolds containing aligned ﬁ-
bres are able to direct the growth of primary human valvular interstitial
cells along the scaffold axis (Masoumi et al., 2014). A similar approach
could be used to mimic the zonal structure and mechanical properties
of native articular cartilage.
There are still many technical challenges associated with the clinical
use of MSCs for the regeneration of degenerate joints. However, we are
starting to overcome some of the practical and conceptual difﬁculties.
Interdisciplinary approaches based on the combination of new genera-
tion biomaterials and cell-based therapies are more likely to lead to
breakthroughs in regenerating musculoskeletal tissues in the future.
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